SCOL Stock Overview
A clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Scandion Oncology A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.16 |
| 52 Week High | SEK 5.64 |
| 52 Week Low | SEK 0.15 |
| Beta | 1.33 |
| 11 Month Change | -23.58% |
| 3 Month Change | -87.82% |
| 1 Year Change | -90.18% |
| 33 Year Change | -99.09% |
| 5 Year Change | n/a |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06
Shareholder Returns
| SCOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.4% | -2.4% | -4.3% |
| 1Y | -90.2% | 18.0% | 12.6% |
Return vs Industry: SCOL underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: SCOL underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| SCOL volatility | |
|---|---|
| SCOL Average Weekly Movement | 37.3% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: SCOL's share price has been volatile over the past 3 months.
Volatility Over Time: SCOL's weekly volatility has increased from 24% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Francois Martelet | www.scandiononcology.com |
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.
Scandion Oncology A/S Fundamentals Summary
| SCOL fundamental statistics | |
|---|---|
| Market cap | SEK 37.57m |
| Earnings (TTM) | -SEK 57.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs SCOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCOL income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 0 |
| Other Expenses | DKK 37.49m |
| Earnings | -DKK 37.48m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SCOL perform over the long term?
See historical performance and comparison